Oramed Pharmaceuticals, Inc [NASDAQ: ORMP] traded at a low on 2025-11-26, posting a -1.04 loss after which it closed the day’ session at $2.85.
The results of the trading session contributed to over 272210 shares changing hands. Over the past one week, the price volatility of Oramed Pharmaceuticals, Inc stands at 8.40% while the volatility over the past one month is 5.99%.
The market cap for ORMP stock reached $113.44 million, with 40.84 million shares outstanding and 33.66 million shares in the current float. Compared to the average trading volume of 156.66K shares, ORMP reached a trading volume of 272210 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Oramed Pharmaceuticals, Inc [ORMP]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ORMP shares is $3.25 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ORMP stock is a recommendation set at 3.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Canaccord Genuity have made an estimate for Oramed Pharmaceuticals, Inc shares, keeping their opinion on the stock as Hold, with their previous recommendation back on January 12, 2023. While these analysts kept the previous recommendation, Cantor Fitzgerald raised their target price to Overweight. The new note on the price target was released on February 18, 2022, representing the official price target for Oramed Pharmaceuticals, Inc stock. Previously, the target price had yet another raise to $27, while Canaccord Genuity analysts kept a Buy rating on ORMP stock.
The Price to Book ratio for the last quarter was 0.57, with the Price to Cash per share for the same quarter was set at 3.38.
How has ORMP stock performed recently?
Oramed Pharmaceuticals, Inc [ORMP] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 14.23. With this latest performance, ORMP shares gained by 20.76% in over the last four-week period, additionally plugging by 27.80% over the last 6 months – not to mention a rise of 17.77% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ORMP stock in for the last two-week period is set at 70.71, with the RSI for the last a single of trading hit 0.17, and the three-weeks RSI is set at 0.14 for Oramed Pharmaceuticals, Inc [ORMP]. The present Moving Average for the last 50 days of trading for this stock 2.42, while it was recorded at 2.66 for the last single week of trading, and 2.26 for the last 200 days.
Oramed Pharmaceuticals, Inc [ORMP]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Oramed Pharmaceuticals, Inc [ORMP] shares currently have an operating margin of -650.55% and a Gross Margin at -5.45%. Oramed Pharmaceuticals, Inc’s Net Margin is presently recorded at 2192.60%.
Oramed Pharmaceuticals, Inc (ORMP) Capital Structure & Debt Analysis
According to recent financial data for Oramed Pharmaceuticals, Inc. ( ORMP), the Return on Equity (ROE) stands at 24.38%, reflecting robust shareholder value creation. The Return on Assets (ROA) is 22.75%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Oramed Pharmaceuticals, Inc’s Return on Invested Capital (ROIC) is 21.51%, showcasing its effectiveness in deploying capital for earnings.
Oramed Pharmaceuticals, Inc (ORMP) Efficiency & Liquidity Metrics
Based on Oramed Pharmaceuticals, Inc’s (ORMP) latest financial statements, the Debt-to-Equity Ratio is 0.00%, indicating its reliance on debt financing relative to shareholder equity.
Oramed Pharmaceuticals, Inc (ORMP) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Oramed Pharmaceuticals, Inc. (ORMP) effectively leverages its workforce, generating an average of $3373076.92 per employee. The company’s liquidity position is robust, with a Current Ratio of 22.24% and a Quick Ratio of 22.24%, indicating strong ability to cover short-term liabilities.
Earnings analysis for Oramed Pharmaceuticals, Inc [ORMP]
With the latest financial reports released by the company, Oramed Pharmaceuticals, Inc posted -0.26/share EPS, while the average EPS was predicted by analysts to be reported at -0.02/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -0.24. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ORMP.
Insider trade positions for Oramed Pharmaceuticals, Inc [ORMP]
There are presently around $18.25%, or 21.11%% of ORMP stock, in the hands of institutional investors. The top three institutional holders of ORMP stocks are: MURCHINSON LTD. with ownership of 1.7 million shares, which is approximately 4.1504%. BML CAPITAL MANAGEMENT, LLC, holding 1.35 million shares of the stock with an approximate value of $$3.47 million in ORMP stocks shares; and BML CAPITAL MANAGEMENT, LLC, currently with $$2.12 million in ORMP stock with ownership which is approximately 2.0142%.
